Keywords: سورفانیب; Renal cell carcinoma; Sequential therapy; Survival; Sunitinib; Sorafenib; Everolimus; Bevacizumab; Axitinib; Temsirolimus; Third-line;
مقالات ISI سورفانیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سورفانیب; Biomarker; Contractility; Erlotinib; FCCP; Isolated heart; Isoproterenol; Rat; Sorafenib; Sunitinib; Verapamil;
Keywords: سورفانیب; Oral cancer; ABT-737; Sorafenib; Apoptosis; Bax; Bak
Keywords: سورفانیب; RET; Sorafenib; Non-small cell lung cancer
Keywords: سورفانیب; Antineoplastic Agents/therapeutic use; Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/drug therapy; SorafenibAntineoplásicos/quimioterapia; Carcinoma Hepatocelular/quimioterapia; Neoplasia do Fígado/quimioterapia; Sorafenib
Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria
Keywords: سورفانیب; Radioactive iodine-refractory differentiated thyroid cancer; Lenvatinib; Sorafenib; Proteinuria; Renal impairment;
Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families
Keywords: سورفانیب; Hepatocellular carcinoma; Sorafenib; Regorafenib; Levnatinib; Invasion; Metastasis; Hepatocellular carcinoma; HCC; Matrix metalloproteinases; MMPs; Tissue inhibitors of MMPs; TIMPs; Extracellular matrix; ECM; Receptor tyrosine kinases; RTKs; Vascular endo
Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas
Keywords: سورفانیب; Hepatocellular carcinoma; BCLC stages B and C; transarterial chemoembolization; sorafenib; prognosis;
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Keywords: سورفانیب; Adjuvant chemotherapy; Renal cell carcinoma; Pazopanib; Sunitinib; Sorafenib; Tyrosine kinase inhibitors;
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study
Keywords: سورفانیب; Bladder cancer; Urothelial carcinoma; Neoadjuvant therapy; Sorafenib; Chemotherapy;
Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival
Keywords: سورفانیب; HCC; hepatocellular carcinoma; CT; computed tomography; MRI; magnetic resonance imaging; mRECIST; modified response evaluation criteria in solid tumors; TACE; transarterial chemoembolization; HAIC; hepatic arterial infusion chemotherapy; ECOG PS; eastern
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
Keywords: سورفانیب; Advanced HCC; Systemic therapy; Sorafenib; Regorafenib;
Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients
Keywords: سورفانیب; Hepatocellular carcinoma; Sorafenib; Cumulative doses; Hand-foot skin reaction; Progression-free survival;
Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses
Keywords: سورفانیب; Sorafenib; Alphavirus; Venezuelan equine encephalitis virus; Eastern equine encephalitis virus; Western equine encephalitis virus; Chikungunya virus; Sindbis virus;
Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy
Keywords: سورفانیب; Sorafenib; siVEGF; Mesoporous silica nanoparticles; Lactobionic acid;
Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma
Keywords: سورفانیب; Superparamagnetic iron oxide nanoparticles (SPIONs); Sorafenib; Hepatocellular carcinoma; Apoptosis; Autophagy; Chemotherapy;
A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs
Keywords: سورفانیب; Angiogenesis inhibitors; DLL4; Human umbilical vein endothelial cell; In vitro 3D model; Microvessel; Notch; Sorafenib; Sprouting angiogenesis; Sunitinib; Vascular endothelial growth factor; 3D; three-dimensional; BSA; bovine serum albumin; CLSM; confocal
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching
Keywords: سورفانیب; BCLC; Barcelona Clinic Liver Cancer; CTP; Child-Turcotte-Pugh; ECOG; Eastern Cooperative Oncology Group; HCC; heptaocellular carcinoma; MVI; macrovascular invasion; SOR; sorafenib;
Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma
Keywords: سورفانیب; Polymeric nanoparticles; Sorafenib; Anti-GPC3 antibody; Targeted delivery; Hepatocellular carcinoma;
Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway
Keywords: سورفانیب; Epithelial mesenchymal transition; Fluvastatin; Hepatic fibrosis; Sorafenib; TGFβ1;
RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma
Keywords: سورفانیب; RASSF6; Sorafenib; Mcl-1; JNK signaling pathway; Apoptosis; Targeted therapy;
Effect of histidine on sorafenib-induced vascular damage: Analysis using novel medaka fish model
Keywords: سورفانیب; Sorafenib; Vascular damage; Hand-foot syndrome; Histidine; Medaka;
Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome
Keywords: سورفانیب; Glycol chitosan; Colonic absorption; Sorafenib; Liposomes; Bioavailability; Eudragit S100;
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats
Keywords: سورفانیب; Cardiopulmonary remodeling; Pulmonary arterial hypertension; Right ventricular hypertrophy; Sorafenib; Toceranib;
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Keywords: سورفانیب; Regorafenib; Sorafenib; Hepatocellular carcinoma; Survival analysis; Treatment outcome;
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT
Keywords: سورفانیب; Silibinin; Sorafenib; Drug combination; Hepatocellular carcinoma; Cancer stem cell;
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma
Keywords: سورفانیب; Hepatocellular carcinoma; Sorafenib; Arterial infusion chemotherapy; FOLFOX; Oxaliplatin; Fluorouracil;
Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma
Keywords: سورفانیب; Hepatocellular carcinoma; Angiogenesis; Chromatin remodeling; Angiopoietin-2; Sorafenib;
Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma
Keywords: سورفانیب; TGF-β; Sorafenib; Lipid-raft/caveolae; Endocytosis/degradation; Hepatic stellate cells;
Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma
Keywords: سورفانیب; Hepatocellular carcinoma; Pregnane X receptor; Multi-drug resistance; Sorafenib; Metabolism and clearance;
Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib
Keywords: سورفانیب; Sorafenib; Oral delivery; Polymersomes; Co-block polymer;
PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure
Keywords: سورفانیب; Sorafenib; Tumor targeting; Hyaluronic acid; Liposome; Prolonged circulation;
Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis
Keywords: سورفانیب; Transarterial chemoembolization; TACE; Sorafenib; Advanced hepatocellular carcinoma; Network meta-analysis;
Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells
Keywords: سورفانیب; Alkylation; Sorafenib; Inflammation; MEK1/2-ERK1/2; Secretome;
A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma
Keywords: سورفانیب; Sorafenib; Advanced osteosarcoma; Denosumab; Everolimus; Novel therapy; Second line; RANKL; Tyrosine kinase; Nexavar; MTORC; Italian Sarcoma Group; Primary bone cancer; MAPK; ERK; Temsirolimus; Bevacizumab;
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension
Keywords: سورفانیب; Multi-kinase inhibitor; Pulmonary arterial hypertension; Pulmonary veno-occlusive disease; Right heart failure; Sorafenib;
Phase I trialPhase I trial of radiation therapy and sorafenib in unresectable liver metastases
Keywords: سورفانیب; Sorafenib; Radiotherapy; Liver metastases;
Phase I trialPhase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study
Keywords: سورفانیب; Palliative radiotherapy; Sorafenib; Drug-radiotherapy interactions; Phase I trial;
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)
Keywords: سورفانیب; NSCLC; erlotinib; sorafenib; EGFR;
Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit
Keywords: سورفانیب; ALBI; Child-Pugh; hepatocellular carcinoma; prognosis; sorafenib;
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma
Keywords: سورفانیب; Elderly; Hepatocellular carcinoma; Safety; Sorafenib;
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes
Keywords: سورفانیب; Antagonism; AKT; BRAF; Dabrafenib; Sorafenib;
Original ResearchLong-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
Keywords: سورفانیب; Acute myeloid leukemia; FLT3-ITD; Hematopoietic stem cell transplantation; Sorafenib;
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS
Keywords: سورفانیب; LC-MS/MS; liquid chromatography coupled with tandem mass spectrometry; SORA; sorafenib; SORA-NO; sorafenib N-oxide; REGO; regorafenib; REGO-M2; N-oxide regorafenib; REGO-M5; N-oxide N-desmethyl regorafenib; HCC; hepatocellular carcinoma; MKI; multikinas
Original ArticleMathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells
Keywords: سورفانیب; Hepatocellular carcinoma; Sorafenib; RAF-MEK-ERK cascade; Protein phosphatases; Mathematical modelling; DUSP; Dual-specificity phosphatases; EGFR; Epidermal Growth Factor Receptor; ERK1/2; Extracellular signal-Regulated Kinase 1/2; HCC; hepatocellular car
Original ResearchPrognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score
Keywords: سورفانیب; Molecular targeted therapy; Liver neoplasms; Prognosis; Sorafenib; Drug therapy;
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry
Keywords: سورفانیب; Hepatocellular cancer; Sorafenib; Liver; Resection; Transplantation; Recurrence; Treatment of recurrent cancer;
Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function
Keywords: سورفانیب; β-Catenin; FH535; Glycolysis; HCC cell metabolism; Hepatocellular carcinoma; Mitochondrial ETC complexes; Mitochondrial respiration; Sorafenib;
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib
Keywords: سورفانیب; AFP; alpha fetoprotein; CI; confidence interval; DNA; deoxyribonucleic acid; EGF; epidermal growth factor; FGF; fibroblast growth factor; G-CSF; granulocyte colony-stimulating factor; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; HR; hazard ratio
Original articleTemozolomide and sorafenib as programmed cell death inducers of human glioma cells
Keywords: سورفانیب; Gliomas; Sorafenib; Temozolomide; Programmed cell death; Heat shock proteins; ER stress;